Get MindMed Updates:
Get MindMed Updates:
Press Release
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
01/20/21
Press Release
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
01/14/21
Press Release
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
01/12/21
Investor Deck
Quarterly Corporate Update
Corporate Update Q&A
Regulation of Human Research with LSD in The United States
Third Quarter 2020 Management's Discussion and Analysis
Third Quarter 2020 Consolidated Financial Statements
Second Quarter 2020 Consolidated Financial Statements
Second Quarter 2020 Management's Discussion and Analysis
Q2 2020 Earnings Call Recording
2019 Audited Annual Consolidated Financial Statements
Year-end 2019 Management's Discussion and Analysis
2019 Year End Earnings Call & Corporate Update
MindMed Sedar Profile
Audit Committee Charter
Compensation Nomination and Governance Charter
Insider Trading Policy
Majority Voting Policy
Policy RE Diversity of Executive Officers
Policy RE Diversity on Board
Privacy Policy
Policy RE Anti-Money Laundering and Anti-Terrorist Financing
Board of Directors Charter
Anti-Bribery and Anti-Corruption Policy
